유럽의 고활성 API 시장 : 분석 및 예측(2023-2033년)

Introduction to Europe Highly Potent API Market

The Europe highly potent API market is projected to reach $16.33 billion by 2033 from $5.98 billion in 2023, growing at a CAGR of 10.57% during the forecast period 2023-2033. The primary factors propelling the expansion of the highly potent API market are the rising incidence of cancer, which boosts the demand for highly potent APIs, and the broadening range of therapeutic applications for these APIs.

Market Introduction

The Europe Highly Potent API market is experiencing significant growth, driven by increasing cancer prevalence and the expanding application of HPAPIs in various therapeutic areas. The region's robust pharmaceutical industry, supported by advanced R&D facilities and stringent regulatory frameworks, enhances market development. Key players in Europe are investing heavily in manufacturing capabilities and collaborative partnerships to meet the rising demand. Additionally, the adoption of innovative technologies and processes ensures the production of high-quality, safe HPAPIs. The market is further fueled by the growing outsourcing trend to specialized contract manufacturing organizations (CMOs) with expertise in handling highly potent compounds, ensuring compliance with safety and environmental regulations, and reducing operational costs for pharmaceutical companies.

Market Segmentation:

Segmentation 1: by Country

• U.K.
• Germany
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Competitive Strategy: The highly potent API market has numerous established players with product and service portfolios. Key players in the Europe highly potent API market analysed and profiled in the study involve established players offering products and services of highly potent API.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, type portfolio, and market penetration.

Some prominent names in the market include:

• Almac Group
• Axplora Group GmbH
• BASF Pharma Solutions
• CordenPharma International
• Helsinn Healthcare SA.
• ICROM
• Lonza
• Merck KGaA
• Sterling Pharma Solutions

Table of Contents

Executive Summary

Scope and Definition

1 Markets

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Trend 1: Advancements in Containment Technologies for Highly Potent APIs
  • 1.1.2 Trend 2: Increasing Investment for Highly Potent API Manufacturing Units
  • 1.1.3 Trend 3: Pharmaceutical Companies Outsourcing Highly Potent APIs Production to CDMOs
• 1.2 Supply Chain /Value Overview
  • 1.2.1 Supply Chain and Risks within the Supply Chain
  • 1.2.2 Value Chain Analysis
• 1.3 Pricing Analysis
• 1.4 Patent Filing Trend (by Year, Country)
• 1.5 Regulatory Landscape
• 1.6 Impact Analysis for Key Global Events - COVID-19
• 1.7 Market Dynamics: Overview
  • 1.7.1 Market Drivers
    • 1.7.1.1 Increasing Incidence of Cancer Leading to Demand in the Adoption of Highly Potent APIs
    • 1.7.1.2 Advancements in Drug Delivery Technologies
    • 1.7.1.3 Expanding Therapeutic Applications of Highly Potent API
  • 1.7.2 Market Opportunities
    • 1.7.2.1 Growing Emphasis on Personalized Medicine
    • 1.7.2.2 Increasing Opportunities for Pharma Companies in Developing Markets
  • 1.7.3 Market Restraints
    • 1.7.3.1 Regulatory Complexity for Highly Potent APIs' Manufacturing
    • 1.7.3.2 High Development and Production Costs

2 Regions

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 France
  • 2.2.5 Germany
  • 2.2.6 U.K.
  • 2.2.7 Spain
  • 2.2.8 Italy
  • 2.2.9 Rest-of-Europe

3 Markets -Competitive Benchmarking & Company Profiles

• 3.1 Next Frontiers
• 3.2 Geographic Assessment
  • 3.2.1 Almac Group
    • 3.2.1.1 Overview
    • 3.2.1.2 Key Developments
    • 3.2.1.3 Top Products/Product/Service Portfolio
    • 3.2.1.4 Top Competitors
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Axplora Group GmbH
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products/Product/Service Portfolio
    • 3.2.2.3 Key Developments
    • 3.2.2.4 Top Competitors
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 BASF SE
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products/Product/Service Portfolio
    • 3.2.3.3 Key Developments
    • 3.2.3.4 Top Competitors
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 CordenPharma International
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products/Product/Service Portfolio
    • 3.2.4.3 Key Developments
    • 3.2.4.4 Top Competitors
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View
  • 3.2.5 Helsinn Healthcare SA.
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products/Product/Service Portfolio
    • 3.2.5.3 Key Developments
    • 3.2.5.4 Top Competitors
    • 3.2.5.5 Key Personnel
    • 3.2.5.6 Analyst View
  • 3.2.6 ICROM
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products/Product/Service Portfolio
    • 3.2.6.3 Top Competitors
    • 3.2.6.4 Key Personnel
    • 3.2.6.5 Analyst View
  • 3.2.7 Lonza
    • 3.2.7.1 Overview
    • 3.2.7.2 Top Products/Product/Service Portfolio
    • 3.2.7.3 Key Developments
    • 3.2.7.4 Top Competitors
    • 3.2.7.5 Key Personnel
    • 3.2.7.6 Analyst View
  • 3.2.8 Merck KGaA
    • 3.2.8.1 Overview
    • 3.2.8.2 Top Products/Product/Service Portfolio
    • 3.2.8.3 Key Developments
    • 3.2.8.4 Top Competitors
    • 3.2.8.5 Key Personnel
    • 3.2.8.6 Analyst View
  • 3.2.9 Sterling Pharma Solutions
    • 3.2.9.1 Overview
    • 3.2.9.2 Top Products/Product/Service Portfolio
    • 3.2.9.3 Key Developments
    • 3.2.9.4 Top Competitors
    • 3.2.9.5 Key Personnel
    • 3.2.9.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast